3 Things Investors Should Know About Mydecine’s Artificial Intelligence & Machine Learning Drug Discovery Program

January 7, 2022

Posted By: Morgan Kervitsky

blog body title

1. What does artificial intelligence (AI) and machine learning (ML) drug discovery mean?

We are using a supercomputer to screen billions of molecules rapidly to determine new compounds that are most likely to become safe and effective drugs. Without AI & ML, drug developers must hypothesize which compounds are likely to become successful drug candidates and then manually manufacture each molecule to test them individually. With our AI-driven drug discovery program, we are able to determine the improved molecules we are looking for prior to further investment in development.

Our drug development program is centered around the development of new compounds for medical use. We use molecules found in nature as building blocks to make improved second and third-generation drugs. This portfolio of new drugs represents enhanced safety, efficacy, stability, dosing, and reduced side effects compared to existing natural and synthetic products. By using AI and ML, we maximize success by focusing on molecules with known medical value when creating new compounds saving us time and money. 

2. How does this target-based model of the classic psychedelic serotonin receptor 5-HT2A impact Mydecine’s drug development pipeline?

Mydecine’s research focuses on psychedelic compounds such as psilocybin and psilocin, psilocybin’s active metabolite. Psilocin interacts with serotonin receptor 5-HT2A, among other serotonin receptors, to induce the psychedelic experience. Creating improved molecules that bind to the 5-HT2A receptor can help patients achieve the desired state of consciousness and neuroplasticity needed to safely and effectively complete their psychedelic-assisted psychotherapy, as currently supported by ongoing clinical research.

Mydecine is excited about enhancing neuroplasticity, the brain’s ability to reorganize its neural pathways to accomplish the needed outcome, to increase the effectiveness of treatments. This property is rare, or absent, in most medications available today and is believed to be highly synergistic with positive outcomes in therapy.

Variability of onset time and poor shelf stability of natural psilocybin make it challenging for proper, scalable implementation for medical use. By using AI to screen psilocybin and psilocin analogs, we are able to more effectively determine how we need to alter these compounds to directly address the concerns of these molecules as they stand in nature.

We continue to use our AI modeling to screen billions of compounds, including all of our patent pending structures. This will further advance our data collection in relation to our recent patent application covering multiple families of psilocin analogs. The application includes solutions to directly address further precision in delivery control, duration of effect, shelf stabilization, and decreased adverse reactions of psilocybin/psilocin all of which are critical for use in the medical setting. Through our AI-driven program, we are able to address continuous improvements in our second and third-generation drugs.

3. How does Mydecine’s AI-driven drug development program improve our intellectual property pipeline, increase efficiency, speed to market, and decrease cost?

By using AI and ML, we are able to screen billions of compounds rapidly and immediately collect data on viable drug candidates. This data enables us to file more patent applications, increasing the value and protection of our IP portfolio.

This program allows us to focus on the changes to novel compounds most likely to succeed. By filtering drug candidates with AI, we are inherently making our investments in the later stages of our drug development more valuable by eliminating potential candidates that are likely to fail early on in the process.

In conclusion, Mydecine’s AI and ML drug discovery program significantly increases the amount of data collected, focuses our attention on drug candidates most likely to succeed (saving us money down the road), and allows us to bring safe effective treatments to market more quickly than our competitors. 

Read Next: Can psilocybin help you quit smoking?